# A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies

> **NCT01607372** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Asthma and Rhinitis

## Interventions

- **DRUG:** GSK2245035
- **DEVICE:** Type 1 amber glass bottle
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01607372
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01607372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01607372, "A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01607372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*